Literature DB >> 23183537

Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing.

Tae Heung Kang1, Barbara Ma, Connie Wang, T-C Wu, Chien-Fu Hung.   

Abstract

The potency of immunotherapies targeting endogenous tumor antigens is hindered by immune tolerance. We created a therapeutic agent comprised of a tumor-homing module fused to a functional domain capable of selectively rendering tumor cells sensitive to foreign antigen-specific CD8(+) T cell-mediated immune attack, and thereby, circumventing concerns for immune tolerance. The tumor-homing module is comprised of a single-chain variable fragment (scFv) that specifically binds to mesothelin (Meso), which is commonly overexpressed in human cancers, including ovarian tumors. The functional domain is comprised of the Fc portion of IgG2a protein and foreign immunogenic CD8(+) T cell epitope flanked by furin cleavage sites (R), which can be recognized and cleaved by furin that is highly expressed in the tumor microenvironment. We show that our therapeutic protein specifically loaded antigenic epitope onto the surface of mesothelin-expressing tumor cells, rendering tumors susceptible to antigen-specific cytotoxic CD8(+) T lymphocytes (CTL)-mediated killing in vitro and in vivo. Our findings have important implications for bypassing immune tolerance to enhance cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183537      PMCID: PMC3589158          DOI: 10.1038/mt.2012.233

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

Review 1.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

2.  Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.

Authors:  T L Wang; M Ling; I M Shih; T Pham; S I Pai; Z Lu; R J Kurman; D M Pardoll; T C Wu
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

Review 3.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

4.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Authors:  Jeffrey R Currier; Ellen G Kuta; Ellen Turk; Lyndsay B Earhart; Larry Loomis-Price; Sylvia Janetzki; Guido Ferrari; Deborah L Birx; Josephine H Cox
Journal:  J Immunol Methods       Date:  2002-02-01       Impact factor: 2.303

5.  Development of a syngeneic mouse model for events related to ovarian cancer.

Authors:  K F Roby; C C Taylor; J P Sweetwood; Y Cheng; J L Pace; O Tawfik; D L Persons; P G Smith; P F Terranova
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

6.  Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.

Authors:  Jose R Conejo-Garcia; Fabian Benencia; Maria-Cecilia Courreges; Eugene Kang; Alisha Mohamed-Hadley; Ronald J Buckanovich; David O Holtz; Ann Jenkins; Hana Na; Lin Zhang; Daniel S Wagner; Dionyssios Katsaros; Richard Caroll; George Coukos
Journal:  Nat Med       Date:  2004-08-29       Impact factor: 53.440

7.  Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.

Authors:  Avital Lev; Roy Noy; Kfir Oved; Hila Novak; Dina Segal; Peter Walden; Dietmar Zehn; Yoram Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

Review 8.  Mesothelin: a new target for immunotherapy.

Authors:  Raffit Hassan; Tapan Bera; Ira Pastan
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

9.  Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.

Authors:  Jun Lu; Yuichiro Higashimoto; Ettore Appella; Esteban Celis
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

10.  Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness.

Authors:  Javier Mercapide; Ricardo Lopez De Cicco; Daniel E Bassi; Javier S Castresana; Gary Thomas; Andres JP Klein-Szanto
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

View more
  7 in total

1.  Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy.

Authors:  Keunok Jung; Min-Jeong Son; Se-Young Lee; Jeong-Ah Kim; Deok-Han Ko; Sojung Yoo; Chul-Ho Kim; Yong-Sung Kim
Journal:  Mol Cancer       Date:  2022-04-22       Impact factor: 41.444

2.  Cancer immunotherapy using a potent immunodominant CTL epitope.

Authors:  Liwen Song; Ming-Chieh Yang; Jayne Knoff; Zu-Yue Sun; T-C Wu; Chien-Fu Hung
Journal:  Vaccine       Date:  2014-09-20       Impact factor: 3.641

3.  Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide.

Authors:  Tae Heung Kang; Jayne Knoff; Benjamin Yang; Ya-Chea Tsai; Liangmei He; Chien-Fu Hung; T-C Wu
Journal:  Cell Biosci       Date:  2013-12-20       Impact factor: 7.133

4.  Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.

Authors:  Liwen Song; Ming-Chieh Yang; Jayne Knoff; T-C Wu; Chien-Fu Hung
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

5.  Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes.

Authors:  Julian P Sefrin; Lars Hillringhaus; Olaf Mundigl; Karin Mann; Doris Ziegler-Landesberger; Heike Seul; Gloria Tabares; Dominic Knoblauch; Andreas Leinenbach; Irene Friligou; Sebastian Dziadek; Rienk Offringa; Valeria Lifke; Alexander Lifke
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

6.  Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide.

Authors:  Po-Hao Feng; Xiaoxu Wang; Louise Ferrall; T-C Wu; Chien-Fu Hung
Journal:  J Immunol Res       Date:  2022-01-04       Impact factor: 4.818

7.  Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.

Authors:  Tae Heung Kang; Jung Hwa Park; Andrew Yang; Hyun Jin Park; Sung Eun Lee; Young Seob Kim; Gun-Young Jang; Emily Farmer; Brandon Lam; Yeong-Min Park; Chien-Fu Hung
Journal:  Nat Commun       Date:  2020-02-28       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.